These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 28268215)

  • 21. Experience and response to a randomised controlled trial of extended-release injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone for opioid use disorder: protocol for a mixed-methods evaluation.
    Lowry N; Cowden F; Day E; Gilvarry E; Johnstone S; Murray R; Kelleher M; Mitcheson L; Marsden J
    BMJ Open; 2022 Oct; 12(10):e067194. PubMed ID: 36270754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction.
    Worley MJ; Heinzerling KG; Shoptaw S; Ling W
    Addiction; 2017 Jul; 112(7):1202-1209. PubMed ID: 28164407
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of transdermal buprenorphine: a randomized, placebo-controlled trial in 289 patients with severe cancer pain.
    Poulain P; Denier W; Douma J; Hoerauf K; Samija M; Sopata M; Wolfram G
    J Pain Symptom Manage; 2008 Aug; 36(2):117-25. PubMed ID: 18411010
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Buprenorphine implants in medical treatment of opioid addiction.
    Chavoustie S; Frost M; Snyder O; Owen J; Darwish M; Dammerman R; Sanjurjo V
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):799-807. PubMed ID: 28571505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Open-label, rapid initiation pilot study for extended-release buprenorphine subcutaneous injection.
    Hassman H; Strafford S; Shinde SN; Heath A; Boyett B; Dobbins RL
    Am J Drug Alcohol Abuse; 2023 Jan; 49(1):43-52. PubMed ID: 36001871
    [No Abstract]   [Full Text] [Related]  

  • 26. Safety of a Rapidly Dissolving Buprenorphine/Naloxone Sublingual Tablet (BNX-RDT) for Treatment of Opioid Dependence: A Multicenter, Open-label Extension Study.
    Hoffman K; Peyton ML; Sumner M
    J Addict Med; 2017; 11(3):217-223. PubMed ID: 28353467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Buprenorphine/Naloxone dose and pain intensity among individuals initiating treatment for opioid use disorder.
    Becker WC; Ganoczy D; Fiellin DA; Bohnert AS
    J Subst Abuse Treat; 2015 Jan; 48(1):128-31. PubMed ID: 25312475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preliminary buprenorphine sublingual tablet pharmacokinetic data in plasma, oral fluid, and sweat during treatment of opioid-dependent pregnant women.
    Concheiro M; Jones HE; Johnson RE; Choo R; Huestis MA
    Ther Drug Monit; 2011 Oct; 33(5):619-26. PubMed ID: 21860340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Medication treatment for opioid use disorder in expectant mothers (MOMs): Design considerations for a pragmatic randomized trial comparing extended-release and daily buprenorphine formulations.
    Winhusen T; Lofwall M; Jones HE; Wilder C; Lindblad R; Schiff DM; Wexelblatt S; Merhar S; Murphy SM; Greenfield SF; Terplan M; Wachman EM; Kropp F; Theobald J; Lewis M; Matthews AG; Guille C; Silverstein M; Rosa C
    Contemp Clin Trials; 2020 Jun; 93():106014. PubMed ID: 32353544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single high-dose buprenorphine for opioid craving during withdrawal.
    Ahmadi J; Jahromi MS; Ghahremani D; London ED
    Trials; 2018 Dec; 19(1):675. PubMed ID: 30526648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Understanding abuse of buprenorphine/naloxone film versus tablet products using data from ASI-MV® substance use disorder treatment centers and RADARS® System Poison Centers.
    Butler SF; Black RA; Severtson SG; Dart RC; Green JL
    J Subst Abuse Treat; 2018 Jan; 84():42-49. PubMed ID: 29195592
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomised controlled trial of sublingual buprenorphine-naloxone film versus tablets in the management of opioid dependence.
    Lintzeris N; Leung SY; Dunlop AJ; Larance B; White N; Rivas GR; Holland RM; Degenhardt L; Muhleisen P; Hurley M; Ali R
    Drug Alcohol Depend; 2013 Jul; 131(1-2):119-26. PubMed ID: 23317685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Buprenorphine treatment for opioid use disorder: recent progress.
    Parida S; Carroll KM; Petrakis IL; Sofuoglu M
    Expert Rev Clin Pharmacol; 2019 Aug; 12(8):791-803. PubMed ID: 31232604
    [No Abstract]   [Full Text] [Related]  

  • 34. Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 microg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12-week, randomized, open-label, controlled, parallel-group noninferiority study.
    Karlsson M; Berggren AC
    Clin Ther; 2009 Mar; 31(3):503-13. PubMed ID: 19393841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relative bioavailability of different buprenorphine formulations under chronic dosing conditions.
    Strain EC; Moody DE; Stoller KB; Walsh SL; Bigelow GE
    Drug Alcohol Depend; 2004 Apr; 74(1):37-43. PubMed ID: 15072805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use Disorder.
    Dong R; Wang H; Li D; Lang L; Gray F; Liu Y; Laffont CM; Young M; Jiang J; Liu Z; Learned SM
    Drugs R D; 2019 Sep; 19(3):255-265. PubMed ID: 31197606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine.
    Lim SCB; Schug S; Krishnarajah J
    Pain Med; 2019 Jan; 20(1):143-152. PubMed ID: 29309700
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effectiveness of different singly administered high doses of buprenorphine in reducing suicidal ideation in acutely depressed people with co-morbid opiate dependence: a randomized, double-blind, clinical trial.
    Ahmadi J; Jahromi MS; Ehsaei Z
    Trials; 2018 Aug; 19(1):462. PubMed ID: 30157924
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers.
    Jönsson M; Mundin G; Sumner M
    Eur J Pharm Sci; 2018 Sep; 122():125-133. PubMed ID: 29940217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world outcomes with extended-release buprenorphine (XR-BUP) in a low threshold bridge clinic: A retrospective case series.
    Peckham AM; Kehoe LG; Gray JR; Wakeman SE
    J Subst Abuse Treat; 2021 Jul; 126():108316. PubMed ID: 34116808
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.